Invitrogen™ CD262 (DR5) Monoclonal Antibody (MD5-1), Functional Grade, eBioscience™, Invitrogen™

Catalog No.	Quantity
50-146-03	500 μg
50-146-01	50 μg

Catalog No. 50-146-03 Supplier Invitrogen™ Supplier No. 16588385

Description

Armenian Hamster Monoclonal Antibody

Description: The MD5-1 monoclonal antibody reacts with mouse DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 mRNA is expressed broadly by normal tissue and human antigen is also expressed by some tumor cell lines. Applications Reported: The MD5-1 antibody has been reported for use in flow cytometric analysis. It has also been reported for use in functional assays. Applications Tested: The MD5-1 antibody has been tested by flow cytometric analysis of mouse DR5-transfected cells. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

Specifications

• Antigen: CD262 (DR5)
• Applications: Flow Cytometry, Functional Assay
• Classification: Monoclonal
• Clone: MD5-1
• Concentration: 1 mg/mL
• Conjugate: Functional Grade
• Formulation: PBS with no preservative; pH 7.2
• Gene: TNFRSF10B
• Gene Accession No.: Q9QZM4
• Gene Alias: apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
• Gene Symbols: TNFRSF10B
• Host Species: Armenian Hamster
• Purification Method: Affinity chromatography
• Quantity: 500 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 21933
• Target Species: Mouse
• Content And Storage: 4°C
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG

Safety and Handling

WARNING: Cancer and Reproductive Harm - www.P65Warnings.ca.gov

For Research Use Only.